COMPANY

Allotera Therapeutics

HQ: St. Louis, MO source · alloteratx.com ↗

Keywords: oncology CRISPR CAR-T cancer T-cell Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Acute Myeloid Leukemia Colorectal Cancer Metastatic Squamous Cell Carcinoma of Head and Neck T-cell Lymphoblastic Lymphoma WU-CART-007 WU-NK-101 Genetic: WU-CART-007

Location: St. Louis, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Raises and deals from press releases

Formerly Wugen

Raise Undisclosed round · $35M · announced Jul 8, 2026 Company release ↗
Source quote
- Jul 8, 2026 · Company release ↗
  “Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers”
Raise Equity financing · $115M · announced Aug 27, 2025 Company release ↗
Source quote
- Aug 27, 2025 · Company release ↗
  “today announced the closing of $115 million equity financing led by Fidelity Management & Research Company”

Raises announced in these releases: $150M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 8, 2026 Raise Undisclosed round · $35M source ↗
Aug 27, 2025 Raise Equity financing · $115M source ↗
Jan 31, 2025 Trial start 2: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) source ↗
May 21, 2024 Trial start 1: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab source ↗
Jul 1, 2023 Trial start 1: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) source ↗
Aug 22, 2022 Trial start —: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 source ↗
Jan 14, 2022 Trial start 1: A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · 2 · A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) · NCT06514794
Jul 1, 2037 (ESTIMATED) · · A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 · NCT05509855

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06514794	A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)	2	Recruiting	Jan 31, 2025	Dec 30, 2026 (estimated)
NCT05470140	A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	1	Completed	Jul 1, 2023	Oct 8, 2024 (actual)
NCT04984356	A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL	1	Completed	Jan 14, 2022	Aug 8, 2024 (actual)
NCT05674526	A Phase 1b Study of WU-NK-101 in Combination With Cetuximab	1	Active, not recruiting	May 21, 2024	Sep 30, 2025 (estimated)
NCT05509855	A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007	Not listed	Enrolling by invitation	Aug 22, 2022	Jul 1, 2037 (estimated)